Evaluating Myocardial Ischemia and Sympathetic Innervation in Patients with Chronic Kidney Disease before and during Renal Replacement Therapy using 99mTc-tetrofosmin and 123I-MIBG imaging

Evaluating Myocardial Ischemia and Sympathetic Innervation in Patients with Chronic Kidney Disease before and during Renal Replacement Therapy using 99mTc-tetrofosmin and 123I-MIBG imaging - Myocardial Ischemia Innervation imaging

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37178

Enrollment

Registered

2008-09-25

Start date

2010-05-10

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease dialysis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: end-stage chronic kidney disease (stage 5)

Exclusion criteria

Exclusion criteria: Patients with acute or previous myocardial infarction within 6 months prior to inclusion, angina pectoris within 6 months prior to inclusion, known coronary artery disease within 6 months prior to inclusion, or recent acute cardiac decompensation, as defined by sudden accumulation of pulmonary congestion or peripheral oedema, pregnancy, M. Parkinson, diabetes mellitus, Diffuse Lewy Body disease. Use of tricyclic antidepressant agents (interferes with 123I- MIBG uptake). Participation to a previous protocol involving radioactivity in the past year.

Design outcomes

Primary

Measure	Time frame
Cardiac ischemia and cardial neuropathy in patients with CKD (pre-dialysis) and 3 months after starting HD.	—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results